{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,28]],"date-time":"2026-09-28T16:21:15Z","timestamp":1790612475963,"version":"4.1.0"},"update-to":[{"DOI":"10.1371\/journal.pmed.1004662","type":"new_version","label":"New version","source":"publisher","updated":{"date-parts":[[2025,12,11]],"date-time":"2025-12-11T00:00:00Z","timestamp":1765411200000}}],"reference-count":30,"publisher":"Public Library of Science (PLoS)","issue":"12","license":[{"start":{"date-parts":[[2025,12,8]],"date-time":"2025-12-08T00:00:00Z","timestamp":1765152000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/publicdomain\/zero\/1.0\/"}],"funder":[{"DOI":"10.13039\/100009633","name":"Eunice Kennedy Shriver National Institute of Child Health and Human Development","doi-asserted-by":"publisher","award":["HD091350"],"award-info":[{"award-number":["HD091350"]}],"id":[{"id":"10.13039\/100009633","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100009633","name":"Eunice Kennedy Shriver National Institute of Child Health and Human Development","doi-asserted-by":"publisher","award":["HD091350"],"award-info":[{"award-number":["HD091350"]}],"id":[{"id":"10.13039\/100009633","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100009633","name":"Eunice Kennedy Shriver National Institute of Child Health and Human Development","doi-asserted-by":"publisher","award":["HD091350"],"award-info":[{"award-number":["HD091350"]}],"id":[{"id":"10.13039\/100009633","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100009633","name":"Eunice Kennedy Shriver National Institute of Child Health and Human Development","doi-asserted-by":"publisher","award":["HD091350"],"award-info":[{"award-number":["HD091350"]}],"id":[{"id":"10.13039\/100009633","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100009633","name":"Eunice Kennedy Shriver National Institute of Child Health and Human Development","doi-asserted-by":"publisher","award":["HD091350"],"award-info":[{"award-number":["HD091350"]}],"id":[{"id":"10.13039\/100009633","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100009633","name":"Eunice Kennedy Shriver National Institute of Child Health and Human Development","doi-asserted-by":"publisher","award":["HD091350"],"award-info":[{"award-number":["HD091350"]}],"id":[{"id":"10.13039\/100009633","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["www.plosmedicine.org"],"crossmark-restriction":false},"short-container-title":["PLoS Med"],"abstract":"<jats:sec id=\"sec001\">\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>The risk-to-benefit ratio of using combined oral contraceptive pills (COCPs) and\/or metformin for comprehensive management of polycystic ovary syndrome (PCOS) in women with obesity is unclear. As there is a lack of robust evidence on the impact of these first-line medications on cardiovascular disease (CVD) risk, we compared the effect of COCPs, metformin or both on prevalence of metabolic syndrome (MetS) in participants with hyperandrogenic PCOS and hypothesized that COCPs would increase prevalence of MetS while metformin would decrease prevalence of MetS.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec id=\"sec002\">\n                    <jats:title>Methods and findings<\/jats:title>\n                    <jats:p>\n                      We conducted a multicenter, double-blind, double-dummy, randomized trial (COMET-PCOS) in participants between ages\u2009\u226518 and \u226440 years and body mass index (BMI) \u226525\u2009kg\/m\n                      <jats:sup>2<\/jats:sup>\n                      and \u2264 48\u2009kg\/m\n                      <jats:sup>2<\/jats:sup>\n                      with hyperandrogenic PCOS (defined by the Rotterdam criteria). Participants were randomized 1:1:1 to 24 weeks of low-dose COCPs (20 \u03bcg ethinyl estradiol\/0.15\u2009mg desogestrol), metforminXR (2,000\u2009mg), or both (Combined). The primary outcome, assessed by intention-to-treat analysis, was the effect of the different treatment groups on the prevalence of MetS at the end of study. The analytical model included site, race, and the presence or absence of MetS at the screening visit as covariates. The secondary outcomes included changes in each component of MetS (TG, HDL-C, BP, WC, and fasting glucose levels) over the study period. Of the 240 participants randomly assigned, 20 out of 79 in the COCP group, 16 out of 81 in the metformin group, and 17 out of 80 in the combined group dropped out of the study. A total of 169 participants (70.4%) completed the trial between January 2018 and June 2023 (mean age: 29.5 years; mean BMI: 35.6\u2009kg\/m\n                      <jats:sup>2<\/jats:sup>\n                      ; 70% were White and 23% were Black). The overall prevalence of MetS was 31% at baseline and comparable across groups. At the end of the study, the prevalence of MetS was 26.2% (17\/65) in the metformin group, 28.6% (17\/59) in the Combined group, and 28.8% (17\/59) in COCP group with no significant difference in trend of MetS prevalence between groups (adjusted\n                      <jats:italic>p<\/jats:italic>\n                      \u2009=\u20090.26). Waist circumference (mean change (MC) \u22122.23\u2009cm; 95% CI [\u22123.98, \u22120.49];\n                      <jats:italic>p<\/jats:italic>\n                      \u2009=\u20090.01), BMI (MC \u22120.49\u2009kg\/m\n                      <jats:sup>2<\/jats:sup>\n                      ; 95% CI [\u22120.88, \u22120.10];\n                      <jats:italic>p<\/jats:italic>\n                      \u2009=\u20090.01), and android fat mass measured by DXA (MC \u2212167\u2009g; 95% CI [\u2212264, \u221271[;\n                      <jats:italic>p<\/jats:italic>\n                      \u2009&lt;\u20090.001) decreased in the COCP group over the study period whilst there was no statistically significant changes in these parameters in the metformin only group when compared to baseline.. In the metformin and Combined groups, the majority of participants (&gt;64%) reported diarrhea, while 24.1% in the COCP group reported uterine bleeding. The main methodologic limitation of the study is the potential lack of power to detect differences in secondary outcomes.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec id=\"sec003\">\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>In participants with hyperandrogenic PCOS and overweight\/obesity, low-dose COCPs effectively managed PCOS symptoms without increasing prevalence of MetS. Our findings challenge the current practice of using metformin alone or with COCPs for lowering cardiometabolic risk.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec id=\"sec004\">\n                    <jats:title>Trial registration<\/jats:title>\n                    <jats:p>ClinicalTrials.Gov Identifier: NCT03229057.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1371\/journal.pmed.1004662","type":"journal-article","created":{"date-parts":[[2025,12,8]],"date-time":"2025-12-08T18:32:18Z","timestamp":1765218738000},"page":"e1004662","update-policy":"https:\/\/doi.org\/10.1371\/journal.pmed.corrections_policy","source":"Crossref","is-referenced-by-count":7,"title":["Impact of combined hormonal contraceptives and metformin on metabolic syndrome in women with hyperandrogenic polycystic ovary syndrome and obesity: The COMET-PCOS randomized clinical trial"],"prefix":"10.1371","volume":"22","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-1085-3969","authenticated-orcid":true,"given":"Anuja","family":"Dokras","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christos","family":"Coutifaris","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alan T.","family":"Remaley","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nehal N.","family":"Mehta","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5571-7266","authenticated-orcid":true,"given":"Martin P.","family":"Playford","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8485-2953","authenticated-orcid":true,"given":"Allen R.","family":"Kunselman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christy C.","family":"Stetter","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"William C.","family":"Dodson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Richard S.","family":"Legro","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"340","published-online":{"date-parts":[[2025,12,8]]},"reference":[{"issue":"1","key":"pmed.1004662.ref001","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1038\/s41572-024-00511-3","article-title":"Polycystic ovary syndrome","volume":"10","author":"E Stener-Victorin","year":"2024","journal-title":"Nat Rev Dis Primers"},{"key":"pmed.1004662.ref002","doi-asserted-by":"crossref","DOI":"10.7554\/eLife.85338","article-title":"Direct economic burden of mental health disorders associated with polycystic ovary syndrome: Systematic review and meta-analysis","volume":"12","author":"S Yadav","year":"2023","journal-title":"eLife"},{"issue":"4","key":"pmed.1004662.ref003","doi-asserted-by":"crossref","first-page":"767","DOI":"10.1016\/j.fertnstert.2023.07.025","article-title":"Recommendations from the 2023 international evidence-based guideline for the assessment and management of polycystic ovary syndrome","volume":"120","author":"HJ Teede","year":"2023","journal-title":"Fertil Steril"},{"issue":"5","key":"pmed.1004662.ref004","doi-asserted-by":"crossref","first-page":"924","DOI":"10.1161\/HYPERTENSIONAHA.122.20018","article-title":"Oral contraceptive pills and hypertension: a review of current evidence and recommendations","volume":"80","author":"A Cameron","journal-title":"Hypertension"},{"key":"pmed.1004662.ref005","doi-asserted-by":"crossref","first-page":"1375","DOI":"10.1056\/NEJM199011153232003","article-title":"The effects of different formulations of oral contraceptive agents on lipid and carbohydrate metabolism","volume":"323","author":"I Godsland","year":"1990","journal-title":"N Engl J Med"},{"issue":"1","key":"pmed.1004662.ref006","doi-asserted-by":"crossref","first-page":"191","DOI":"10.1093\/humrep\/deq301","article-title":"The association between the combined oral contraceptive pill and insulin resistance, dysglycemia and dyslipidemia in women with polycystic ovary syndrome: a systematic review and meta-analysis of observational studies","volume":"26","author":"IJ Halperin","year":"2011","journal-title":"Hum Reprod"},{"issue":"6","key":"pmed.1004662.ref007","doi-asserted-by":"crossref","first-page":"3236","DOI":"10.1210\/jc.2004-1843","article-title":"Changes in glucose tolerance over time in women with polycystic ovary syndrome: a controlled study","volume":"90","author":"RS Legro","year":"2005","journal-title":"J Clin Endocrinol Metab"},{"issue":"3","key":"pmed.1004662.ref008","article-title":"Lipid levels in polycystic ovary syndrome: systematic review and meta-analysis","volume":"95","author":"RA Wild","year":"2011","journal-title":"Fertil Steril"},{"issue":"5","key":"pmed.1004662.ref009","article-title":"Cardiovascular and metabolic profiles amongst different polycystic ovary syndrome phenotypes: who is really at risk?","volume":"102","author":"NMP Daan","year":"2014","journal-title":"Fertil Steril"},{"issue":"11","key":"pmed.1004662.ref010","doi-asserted-by":"crossref","first-page":"4048","DOI":"10.1210\/jc.2015-2778","article-title":"Randomized controlled trial of preconception interventions in infertile women with polycystic ovary syndrome","volume":"100","author":"RS Legro","year":"2015","journal-title":"J Clin Endocrinol Metab"},{"issue":"1","key":"pmed.1004662.ref011","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1056\/NEJMct0707092","article-title":"Metformin for the treatment of the polycystic ovary syndrome","volume":"358","author":"JE Nestler","year":"2008","journal-title":"N Engl J Med"},{"issue":"2","key":"pmed.1004662.ref012","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1111\/jcpt.12379","article-title":"Metformin prescription patterns among US adolescents aged 10-19 years: 2009-2013","volume":"41","author":"T Wang","year":"2016","journal-title":"J Clin Pharm Ther"},{"issue":"2","key":"pmed.1004662.ref013","doi-asserted-by":"crossref","DOI":"10.1210\/clinem\/dgad465","article-title":"Metformin and combined oral contraceptive pills in the management of polycystic ovary syndrome: a systematic review and meta-analysis","volume":"109","author":"J Melin","year":"2024","journal-title":"J Clin Endocrinol Metab"},{"issue":"1","key":"pmed.1004662.ref014","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1055\/a-0806-8281","article-title":"Relationships between biochemical markers of hyperandrogenism and metabolic parameters in women with polycystic ovary syndrome: a systematic review and meta-analysis","volume":"51","author":"M Amiri","year":"2019","journal-title":"Horm Metab Res"},{"issue":"8","key":"pmed.1004662.ref015","article-title":"Metformin versus the combined oral contraceptive pill for hirsutism, acne, and menstrual pattern in polycystic ovary syndrome","volume":"8","author":"E Fraison","year":"2020","journal-title":"Cochrane Database Syst Rev"},{"issue":"1","key":"pmed.1004662.ref016","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1055\/s-0038-1667155","article-title":"Knowledge and practices regarding polycystic ovary syndrome among physicians in europe, north america, and internationally: an online questionnaire-based study","volume":"36","author":"M Gibson-Helm","year":"2018","journal-title":"Semin Reprod Med"},{"issue":"2","key":"pmed.1004662.ref017","first-page":"94","article-title":"Implementation of international guidelines for polycystic ovary syndrome: barriers and facilitators among gynecologists and primary care providers","volume":"3","author":"IT Lee","year":"2022","journal-title":"F S Rep"},{"issue":"2","key":"pmed.1004662.ref018","first-page":"604","article-title":"Delayed diagnosis and a lack of information associated with dissatisfaction in women with polycystic ovary syndrome","volume":"102","author":"M Gibson-Helm","year":"2017","journal-title":"J Clin Endocrinol Metab"},{"issue":"9710","key":"pmed.1004662.ref019","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1016\/S0140-6736(09)61794-3","article-title":"The metabolic syndrome","volume":"375","author":"RH Eckel","year":"2010","journal-title":"Lancet"},{"issue":"16","key":"pmed.1004662.ref020","doi-asserted-by":"crossref","first-page":"1640","DOI":"10.1161\/CIRCULATIONAHA.109.192644","article-title":"Harmonizing the metabolic syndrome: a joint interim statement of the International Diabetes Federation Task Force on Epidemiology and Prevention; National Heart, Lung, and Blood Institute; American Heart Association; World Heart Federation; International Atherosclerosis Society; and International Association for the Study of Obesity","volume":"120","author":"KGMM Alberti","year":"2009","journal-title":"Circulation"},{"issue":"2","key":"pmed.1004662.ref021","doi-asserted-by":"crossref","first-page":"530","DOI":"10.1016\/j.fertnstert.2013.10.055","article-title":"Black women with polycystic ovary syndrome (PCOS) have increased risk for metabolic syndrome and cardiovascular disease compared with white women with PCOS [corrected]","volume":"101","author":"JK Hillman","year":"2014","journal-title":"Fertil Steril"},{"issue":"10","key":"pmed.1004662.ref022","doi-asserted-by":"crossref","first-page":"829","DOI":"10.1111\/j.1467-789X.2011.00900.x","article-title":"Adipose tissue dysfunction and hypertriglyceridemia: mechanisms and management","volume":"12","author":"AP van de Woestijne","year":"2011","journal-title":"Obes Rev"},{"key":"pmed.1004662.ref023","article-title":"Effects of oral contraceptives on metabolic profile in women with polycystic ovary syndrome: A meta-analysis comparing products containing cyproterone acetate with third generation progestins","author":"M Amiri","year":"2023","journal-title":"J Endocrinol Invest"},{"issue":"22","key":"pmed.1004662.ref024","doi-asserted-by":"crossref","first-page":"2555","DOI":"10.1016\/j.jacc.2018.01.083","article-title":"Endogenous sex hormones and incident cardiovascular disease in post-menopausal women","volume":"71","author":"D Zhao","year":"2018","journal-title":"J Am Coll Cardiol"},{"key":"pmed.1004662.ref025","doi-asserted-by":"crossref","first-page":"5150684","DOI":"10.1155\/2020\/5150684","article-title":"The effect of metformin on polycystic ovary syndrome in overweight women: a systematic review and meta-analysis of randomized controlled trials","volume":"2020","author":"Y Guan","year":"2020","journal-title":"Int J Endocrinol"},{"issue":"6","key":"pmed.1004662.ref026","doi-asserted-by":"crossref","first-page":"1113","DOI":"10.1210\/jcem-54-6-1113","article-title":"High density lipoprotein-2 and hepatic lipase: reciprocal changes produced by estrogen and norgestrel","volume":"54","author":"MJ Tikkanen","year":"1982","journal-title":"J Clin Endocrinol Metab"},{"issue":"5","key":"pmed.1004662.ref027","doi-asserted-by":"crossref","first-page":"739","DOI":"10.1111\/cen.13310","article-title":"Impact of hormonal contraception and weight loss on high-density lipoprotein cholesterol efflux and lipoprotein particles in women with polycystic ovary syndrome","volume":"86","author":"A Dokras","year":"2017","journal-title":"Clin Endocrinol (Oxf)"},{"issue":"5","key":"pmed.1004662.ref028","doi-asserted-by":"crossref","first-page":"560","DOI":"10.1093\/humupd\/dmv025","article-title":"Metformin and lifestyle modification in polycystic ovary syndrome: systematic review and meta-analysis","volume":"21","author":"N Naderpoor","year":"2015","journal-title":"Hum Reprod Update"},{"key":"pmed.1004662.ref029","article-title":"Metformin adherence and discontinuation among patients with type 2 diabetes: a retrospective cohort study","volume":"20","author":"Y Tanga","year":"2020","journal-title":"J Clin Trans Endo"},{"issue":"4","key":"pmed.1004662.ref030","doi-asserted-by":"crossref","first-page":"1053","DOI":"10.1016\/j.fertnstert.2012.06.035","article-title":"Comparative study of the therapeutic effects of oral contraceptive pills containing desogestrel, cyproterone acetate, and drospirenone in patients with polycystic ovary syndrome","volume":"98","author":"SM Bhattacharya","year":"2012","journal-title":"Fertil Steril"}],"updated-by":[{"DOI":"10.1371\/journal.pmed.1004662","type":"new_version","label":"New version","source":"publisher","updated":{"date-parts":[[2025,12,11]],"date-time":"2025-12-11T00:00:00Z","timestamp":1765411200000}}],"container-title":["PLOS Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pmed.1004662","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,12,11]],"date-time":"2025-12-11T18:51:13Z","timestamp":1765479073000},"score":1,"resource":{"primary":{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pmed.1004662"}},"subtitle":[],"editor":[{"given":"Eszter","family":"Vanky","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"editor"}]}],"short-title":[],"issued":{"date-parts":[[2025,12,8]]},"references-count":30,"journal-issue":{"issue":"12","published-online":{"date-parts":[[2025,12,8]]}},"URL":"https:\/\/doi.org\/10.1371\/journal.pmed.1004662","relation":{},"ISSN":["1549-1676"],"issn-type":[{"value":"1549-1676","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,12,8]]}}}